Loading...
•
Dec 31, 2019
Kiniksa Q4 2019 Earnings Report
Kiniksa reported fourth quarter and full-year 2019 financial results.
Key Takeaways
Kiniksa Pharmaceuticals reported their fourth quarter and full-year 2019 financial results, highlighting recent pipeline activity and year-end 2019 cash reserves of $233 million.
Clinical data readouts are expected throughout 2020 for rilonacept, mavrilimumab, KPL-716, and KPL-404.
Year-end 2019 cash reserves were $233 million.
An interim readout from the KPL-716 Phase 2a trial in prurigo nodularis is expected by the end of April.
Kiniksa is focused on discovering, acquiring, developing, and commercializing therapeutic medicines.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...